Author + information
- Amartya Kundu,
- Partha Sardar,
- Sreeparna Ghosh,
- Saurav Chatterjee and
- Wilbert Aronow
Colchicine has recently gained popularity as an alternative to empiiric anti-inflammatory therapy for treatment of pericarditis. However, conclusive data is lacking regarding the overall benefit of colchicine for prevention of pericarditis and its most feared complication- cardiac tamponade.
We searched Medline, EMBASE and the Cochrane Library up to October 1st, 2015 for randomized controlled trials (RCTs) comparing colchicine with control for outcomes of both pericarditis (acute or recurrent pericarditis, and/or post pericardiotomy syndrome) and cardiac tamponade. Safety end-point was overall incidence of adverse effects. The random effects model of DerSimonian and Laird was used. Statistical analysis was performed using Review Manager (RevMan) version 5.3.
Seven RCTs including a total of 1361 patients were included in the final analysis. Compared to control, colchicine significantly reduced the risk of pericarditis [Odds Ratio (OR) 0.34, 95 % Confidence Interval (CI) 0.26 to 0.45] (Figure A). However, no benefit was observed with colchicine for reducing the incidence of cardiac tamponade [OR 0.49, 95 % CI 0.2 to 1.16] (Figure B). Colchicine was not associated with higher rates of adverse effects compared to control [OR 1.42, 95 % CI 0.96 to 2.09] (Figure C).
Colchicine is effective for prevention of pericarditis without any significant increase in adverse events. However, there is no evidence that colchicine reduces the risk of cardiac tamponade.
Poster Area, South Hall A1
Saturday, April 02, 2016, 10:00 a.m.-10:45 a.m.
Session Title: Contemporary Issues in Preventive Cardiology
Abstract Category: 33. Prevention: Clinical
Presentation Number: 1120-394
- 2016 American College of Cardiology Foundation